Therapeutic perspective on vascular cognitive impairment

Publication date: Available online 17 May 2019Source: Pharmacological ResearchAuthor(s): Kensuke Toyama, Joshua M. Spin, Masaki Mogi, Philip S. TsaoAbstractDementia is one of the greatest public health concerns for the modern aging world. Over the last decade, most researchers developing new therapeutic strategies for dementia have focused on amyloid-β. In contrast, numerous recent studies have indicated that vascular risk factors are associated with various forms of dementia, and that in fact most forms of dementia can be considered an extension of vascular disease. Accordingly, it is sensible to pursue treatment approaches that focus on the blood vessels. Blood-brain barrier (BBB) disruptions in the white matter of patients with vascular cognitive impairment (VCI) have been observed using imaging analysis, and might be potential targets for novel VCI treatment. Tight junctions between cerebral endothelial cells play an important role in the function of the BBB, and recent studies have demonstrated the essential role of microRNAs in regulating tight junctions. Further elucidation of the mechanisms of tight junction-disruption in dementia are likely to lead to promising novel treatments.In this article, we summarize current knowledge regarding microRNAs and vascular cognitive impairment and the possibility of utilizing microRNAs as biomarkers for BBB dysfunction, and seek to envision future therapeutic strategies.Graphical abstract
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research

Related Links:

On Episode 85 of Health in 2 Point 00, it’s our last night in Helsinki. In this episode, Jess asks me about GE selling off Ventures, Neurotrack raising $21 million to detect and track dementia, and Allscripts acquiring ZappRx, a prescribing tool. Also, find out my favorite things from Health 2.0 HIMSS Europe, including a cool pill tracker, Popit, and a great panel on femtech (even though there were not enough men in the room). —Matthew Holt
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health 2.0 Health in 2 Point 00 Health Tech Health Technology HIMSS Jessica DaMassa Matthew Holt Allscripts GE Health 2.0 HIMSS Europe Source Type: blogs
The federal government released a national strategy on dementia on Monday that focuses on preventing the affliction, supporting caregivers and finding cures.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Toronto Source Type: news
Scientists find a key difference between Alzheimer's and frontotemporal dementia: the latter affects a person's 'moral emotions' while the former does not.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
“We have a lot of history to show off here, so it's a great way for individuals to tap into their senses to help recall memories.” ... You are leaving and going to the website of our trust...
Source: News - Category: American Health Source Type: news
Authors: Li H, Habes M, Wolk DA, Fan Y, Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Study of Aging Abstract INTRODUCTION: It is challenging at baseline to predict when and which individuals who meet criteria for mild cognitive impairment (MCI) will ultimately progress to Alzheimer's disease (AD) dementia. METHODS: A deep learning method is developed and validated based on magnetic resonance imaging scans of 2146 subjects (803 for training and 1343 for validation) to predict MCI subjects' progression to AD dementia in a time-to-event analysis setting. RESUL...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Strandberg TE, Tienari PJ PMID: 31201097 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
AbstractMelatonin, a pineal gland synthesized neurohormone is known as a multifunctioning pleiotropic agent which has a wide range of neuroprotective role in manifold age-related neurodegenerative disorders especially Alzheimer ’s diseases (AD). AD is a devastating neurodegenerative disorder and common form of dementia which is defined by abnormal and excessive accumulation of several toxic peptides including amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs). The Alzheimer’s dementia relates to atrophic chang es in the brain resulting in loss of memory, cognitive dysfunction, and impairments o...
Source: Molecular Neurobiology - Category: Neurology Source Type: research
This study tested these competing hypotheses. Registry data were extracted on 51,752 Israeli residents without dementia from September 2002 to January 2012; individuals were born between 1901 and 1945, alive on January 2012, and followed ‐up for the risk of dementia between January 2013 and October 2017. Groups were classified as exposed to the European Holocaust, based on government recognition, or unexposed. Hazard ratios (HRs) from Cox regression models were used to quantify the risk of dementia between the groups, adjusting for demographic and diagnostic covariates; additionally, 12 sensitivity analyses were computed...
Source: Journal of Traumatic Stress - Category: Psychiatry & Psychology Authors: Tags: RESEARCH ARTICLE Source Type: research
AbstractAging is a major risk factor for vascular cognitive impairment and dementia (VCID). Recent studies demonstrate that cerebromicrovascular dysfunction plays a causal role in the development of age-related cognitive impairment, in part via disruption of neurovascular coupling (NVC) responses. NVC (functional hyperemia) is responsible for adjusting cerebral blood flow to the increased energetic demands of activated neurons, and in preclinical animal models of aging, pharmacological restoration of NVC is associated with improved cognitive performance. To translate these findings, there is an increasing need to develop n...
Source: AGE - Category: Geriatrics Source Type: research
More News: Brain | Dementia | Drugs & Pharmacology | International Medicine & Public Health | Neurology | Study